Evogene Ltd (NASDAQ:EVGN), a leading Israeli computational biology company, announced its financial results for the quarter ending September 30, 2023.
Q3 2023 Financial Highlights
- Revenue for the third quarter of 2023 was $3.8 million, a notable increase compared to the $466 thousand in the same period of 2022.
- Net loss reported for Q3 2023 was $3.9 million.
- Gross profit significantly increased to $3.3 million compared to the $346 thousand in Q3 2022.
- Adjusted EBITDA for this quarter was not reported by the company.